Beiersdorf stock weighs Derma strength against NIVEA pressure

Beiersdorf's third-quarter update from October 27 left investors weighing strong growth in Derma and La Prairie against continued pressure on NIVEA. The company maintained its 2026 outlook, while HSBC later downgraded the stock to Hold and reduced its price target.

Beiersdorf reported group sales of 2.362 billion euros in the third quarter, down 1.3 percent organically. The Consumer Business segment declined 0.7 percent organically, but several growth businesses provided support.

Derma Growth Offsets NIVEA Weakness

Derma, which includes Eucerin and Aquaphor, delivered organic sales growth of 10.6 percent in the quarter. La Prairie accelerated to 8.5 percent, supported by strong momentum in China, while Health Care grew 5.7 percent on demand for wound-care products.

NIVEA sales fell 4.9 percent organically. Beiersdorf attributed the performance to temporary sell-in headwinds, trade-related tensions and destocking. The company said sales dynamics improved compared with the second quarter and that global sell-out continued to grow. Management also said the NIVEA turnaround plan was progressing, with initiatives focused on innovation, value-for-money positioning and stronger local relevance.

The tesa business remained another drag, with organic sales down 4.3 percent as semiconductor shortages weighed on its Electronics business. Outside Electronics, parts of the Industry portfolio developed positively, including Electrical Systems and Automotive.

Guidance Holds Despite Uneven Trends

Beiersdorf continues to expect a low-single-digit organic sales decline for the Consumer Business segment in 2026 and a Consumer EBIT margin excluding special factors of at least 11.0 percent. At group level, management retained its forecast for a low-single-digit organic sales decline and an adjusted EBIT margin of at least 11.8 percent.

The company expects temporary retail pressures to fade gradually by year-end, but the fourth quarter remains a demanding test because of a tougher comparison base. The NIVEA recovery therefore depends on whether improving shopper demand can translate into stronger sales while the company manages inventory and retailer relationships.

Investing.com, citing Reuters, reported on November 2 that HSBC cut its rating from Buy to Hold and lowered its price target from 90 euros to 88 euros. The bank pointed to slower NIVEA shopper sales and limited room for margin expansion in 2027. HSBC also reduced its 2027 earnings-per-share forecast to 4.17 euros from 4.22 euros.

Beiersdorf stock traded at 85.02 euros on Lang & Schwarz at 10:00 CET on Tuesday, November 10, 2026, 1.46 percent above the Xetra close of Monday, November 9, 2026.

Market participants are also tracking the DAX market environment as they assess the balance between defensive consumer demand and company-specific execution.

More news and analyses on Beiersdorf stock.